Stephens Consulting LLC Buys 180 Shares of Johnson & Johnson (NYSE:JNJ)

Stephens Consulting LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,937 shares of the company’s stock after buying an additional 180 shares during the period. Stephens Consulting LLC’s holdings in Johnson & Johnson were worth $575,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. GUNN & Co INVESTMENT MANAGEMENT INC. increased its holdings in Johnson & Johnson by 1,194.9% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after acquiring an additional 218,949 shares during the period. Heritage Financial Services LLC grew its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. Heritage Financial Services LLC now owns 10,269 shares of the company’s stock worth $1,609,000 after buying an additional 177 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in Johnson & Johnson by 4.8% during the 4th quarter. Citizens Financial Group Inc. RI now owns 107,589 shares of the company’s stock valued at $16,863,000 after purchasing an additional 4,954 shares during the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth approximately $2,467,000. Finally, Addison Advisors LLC lifted its stake in shares of Johnson & Johnson by 5.9% in the 4th quarter. Addison Advisors LLC now owns 8,903 shares of the company’s stock worth $1,395,000 after purchasing an additional 494 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. Finally, TD Cowen reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $1.63 on Friday, hitting $165.86. The stock had a trading volume of 7,441,042 shares, compared to its average volume of 7,271,470. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a one year low of $143.13 and a one year high of $165.98. The company’s 50-day moving average is $155.34 and its two-hundred day moving average is $153.45. The stock has a market cap of $399.17 billion, a price-to-earnings ratio of 10.34, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.